Download PDF
Thromb Haemost 2013; 110(04): 852-853
DOI: 10.1160/TH13-05-0393
Letters to the Editor
Schattauer GmbH

Evaluation of a commercial assay for ADAMTS13 activity measurement

Sandrine Thouzeau
1   Service d’Hématologie biologique, Hôpital Antoine Béclère, Assistance Publique-Hôpitaux de Paris, Clamart, Université Paris 11, France
2   French Reference Center for Thrombotic Microangiopathies (CNR-MAT), Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Université Paris 6, France
,
Sophie Capdenat
1   Service d’Hématologie biologique, Hôpital Antoine Béclère, Assistance Publique-Hôpitaux de Paris, Clamart, Université Paris 11, France
,
Alain Stepanian
3   Service d’Hématologie biologique, Hôpital Louis Mourier, Assistance Publique-Hôpitaux de Paris, Colombes, Université Paris 7, France
,
Paul Coppo
2   French Reference Center for Thrombotic Microangiopathies (CNR-MAT), Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Université Paris 6, France
4   Département d’Hématologie clinique, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Université Paris 6, Paris, France
,
Agnès Veyradier
1   Service d’Hématologie biologique, Hôpital Antoine Béclère, Assistance Publique-Hôpitaux de Paris, Clamart, Université Paris 11, France
2   French Reference Center for Thrombotic Microangiopathies (CNR-MAT), Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Université Paris 6, France
› Author Affiliations Financial Support: This work was partially supported by a grant from the Délégation Régionale à la Recherche Clinique, Assistance Publique-Hôpitaux de Paris (PHRC AOM05012) and declared at ClinicalTrials.gov record (http://clinicaltrials.gov/show/NCT00426686, study ID number: P051064, Health Authority: France, Ministry of Health).
Further Information

Publication History

Received: 15 May 2013

Accepted after minor revision: 07 June 2013

Publication Date:
01 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008; 3: 249-277.
    CrossrefPubMedGoogle Scholar
  • 2 Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010; 91: 1-19.
    CrossrefPubMedGoogle Scholar
  • 3 Kremer-Hovinga J, Lämmle B. Role of ADAMTS13 in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2012; 2012: 610-616.
    CrossrefPubMedGoogle Scholar
  • 4 Mackie I, Langley K, Chitolie A. et al. Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thromb Haemost 2013; 109: 488-496.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Moatti-Cohen M, Garrec C, Wolf M. et al. for the French Refrence Center for Thrombotic Microangiopathies. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012; 119: 5888-5897.
    CrossrefPubMedGoogle Scholar
  • 6 Kokame K, Nobe Y, Kokubo Y. et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
    CrossrefPubMedGoogle Scholar